Risk factors for the development of antibody-mediated rejection in highly sensitized pediatric kidney transplant recipients

被引:3
|
作者
Kim, Irene K. [1 ]
Choi, Jua [1 ]
Vo, Ashley [1 ]
Kang, Alexis [1 ]
Steggerda, Justin [1 ]
Louie, Sabrina [1 ]
Haas, Mark [2 ]
Mirocha, James [3 ]
Cohen, J. Louis [1 ]
Pizzo, Helen [1 ]
Kamil, Elaine S. [1 ]
Jordan, Stanley C. [1 ]
Puliyanda, Dechu [1 ]
机构
[1] Cedars Sinai Med Ctr, Comprehens Transplant Ctr, Los Angeles, CA 90048 USA
[2] Cedars Sinai Med Ctr, Dept Pathol & Lab Med, Los Angeles, CA 90048 USA
[3] Cedars Sinai Med Ctr, Biostat Core, Los Angeles, CA USA
关键词
ABMR; desensitization; DSA; high sensitization; GLOMERULAR-FILTRATION-RATE; RENAL-ALLOGRAFT PATHOLOGY; INTRAVENOUS IMMUNOGLOBULIN; DESENSITIZATION; FAILURE; ALLOSENSITIZATION; CLASSIFICATION; NEPHRECTOMY; CHILDREN; THERAPY;
D O I
10.1111/petr.13042
中图分类号
R72 [儿科学];
学科分类号
100202 ;
摘要
ABMR remains a significant concern for early graft loss, especially for those who are HS against HLA antigens. We sought to determine the risk factors leading to ABMR in HS pediatric kidney transplant recipients. From January 2009 to December 2015, 16 HS pediatric kidney transplant patients at our center (age range 2-21) were retrospectively reviewed for outcomes and risk factors for ABMR. All HS patients received desensitization with high-dose IVIG/rituximab prior to transplant. Two groups were examined: ABMR(+) (n=7) and ABMR(-) (n=9). Patient survival was 100%; however, one patient in the ABMR(+) group suffered graft loss from ABMR 16months post-transplant. ABMR(+) patients had higher Class I PRA at the time of transplant (Class I: 73.1 +/- 19.1 vs 49.1 +/- 28.3, P=.075), although not statistically significant. ABMR(+) patients were more likely to have a history of transplant nephrectomy (P=.013). The characteristic that most strongly correlated with ABMR was the DSA-RIS (P=.045), a scoring system used to quantify cumulative intensity of all DSA. In conclusion, DSA, as quantified by the RIS at the time of transplant, should be considered as part of the initial allocation strategy and patients with high RIS monitored closely for ABMR post-transplant.
引用
收藏
页数:7
相关论文
共 50 条
  • [21] EFFECTS OF A STANDARDIZED TREATMENT APPROACH ON KIDNEY TRANSPLANT RECIPIENTS WITH ANTIBODY-MEDIATED REJECTION
    Mirioglu, Safak
    Uludag, Omer
    Aksoy, Elif
    Caliskan, Yasar
    Ozluk, Yasemin
    Usta-Akgul, Sebahat
    Ucar, Ali Riza
    Yazici, Halil
    Kilicaslan, Isin
    Turkmen, Aydin
    Sever, Mehmet Sukru
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2019, 34
  • [22] Outcomes of Kidney Transplant Recipients with Antibody-mediated Allograft Rejection: A Retrospective Study
    Al Jurdi, A.
    Goldfarb, L.
    Lafargue, M.
    Azzi, J.
    Riella, L. V.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2021, 21 : 728 - 728
  • [23] Acute Antibody-Mediated Rejection of the Kidney Transplant
    Sladoje-Martinovic, B.
    Orlic, L.
    Zivcic-Cosic, S.
    Racki, S.
    Vuksanovic-Mikulicic, S.
    Maleta, I
    Bubic, I
    Pavletic-Persic, M.
    TRANSPLANTATION, 2012, 94 (10) : 1036 - 1036
  • [24] Prevention of antibody-mediated kidney transplant rejection
    Morath, Christian
    Opelz, Gerhard
    Zeier, Martin
    Suesal, Caner
    TRANSPLANT INTERNATIONAL, 2012, 25 (06) : 633 - 645
  • [25] Outcomes of Acute and Chronic Antibody-Mediated Allograft Rejection in Kidney Transplant Recipients
    Al Jurdi, Ayman
    Cyrino, Laura Goldfarb
    Lafargue, Marie-Camille
    Riella, Leonardo V.
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2021, 32 (10): : 652 - 652
  • [26] Tocilizumab for treatment of chronic active antibody-mediated rejection in kidney transplant recipients
    Boonpheng, Boonphiphop
    De Castro, Iris Camille C.
    Ng, Yue-Harn
    Blosser, Christopher
    Bakthavatsalam, Ramasamy
    Gimferrer, Idoia
    Smith, Kelly
    Leca, Nicolae
    CLINICAL TRANSPLANTATION, 2023, 37 (05)
  • [27] Terminal Complement Inhibition Decreases Antibody-Mediated Rejection in Sensitized Renal Transplant Recipients
    Stegall, M. D.
    Diwan, T.
    Raghavaiah, S.
    Cornell, L. D.
    Burns, J.
    Dean, P. G.
    Cosio, F. G.
    Gandhi, M. J.
    Kremers, W.
    Gloor, J. M.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2011, 11 (11) : 2405 - 2413
  • [28] Bortezomib in the treatment of antibody-mediated rejection in pediatric kidney transplant recipients: A multicenter Midwest Pediatric Nephrology Consortium study
    Kizilbash, Sarah
    Claes, Donna
    Ashoor, Isa
    Chen, Ashton
    Jandeska, Sara
    Matar, Raed Bou
    Misurac, Jason
    Sherbotie, Joseph
    Twombley, Katherine
    Verghese, Priya
    PEDIATRIC TRANSPLANTATION, 2017, 21 (03)
  • [29] Antibody-mediated rejection diagnosed in early protocol biopsies in high immunological risk kidney transplant recipients
    Arana, Carolt
    Hermida, Evelyn
    Rovira, Jordi
    Caro, Jose Luis
    Cucchiari, David
    Larque, Ana Belen
    Palou, Eduard
    Torres, Juan
    Montagud-Marrahi, Enrique
    Cuadrado-Payan, Elena
    Rodriguez, Diana
    Cacho, Judit
    Gonzalez, Angela
    Reinoso, Johanna
    Nicolau, Carlos
    Esforzado, Nuria
    Torregrosa, Vicente
    Pineiro, Gaston
    Revuelta, Ignacio
    Cofan, Federico
    Diekmann, Fritz
    Ventura-Aguiar, Pedro
    Oppenheimer, Federico
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2024,
  • [30] Circulating B Cells With Memory and Antibody-Secreting Phenotypes Are Detectable in Pediatric Kidney Transplant Recipients Before the Development of Antibody-Mediated Rejection
    Fischman, Clara
    Fribourg, Miguel
    Fabrizio, Ginevri
    Cioni, Michela
    Comoli, Patrizia
    Nocera, Arcangelo
    Cardillo, Massimo
    Cantarelli, Chiara
    Gallon, Lorenzo
    Petrosyan, Astgik
    Sacco, Stefano
    Perin, Laura
    Cravedi, Paolo
    TRANSPLANTATION DIRECT, 2019, 5 (09):